PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line ...

Please provide your email address to receive an email when new articles are posted on . A trial of adjuvant immunoadsorption for pemphigus diseases was ended early due to adverse events. The time to ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

Shares of argenx plummeted after lead asset Vyvgart (efgartigimod) failed to meet endpoints in a phase 3 trial for the treatment of pemphigus vulgaris and pemphigus foliaceus. The failure also has ...

Paraneoplastic pemphigus is a rare autoimmune skin condition that causes blisters and oral lesions. It usually develops due to underlying cancer. Treatment is essential for managing symptoms and ...

Shares of argenx SE ARGX were down 25.1% on Dec 20 after the company announced top-line data from the phase III ADDRESS study, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and ...

Controlled study to evaluate physical and psychosocial effects of a standardized in-patient rehabilitation program for patients after allogenic stem cell transplantation No significant financial ...

The acronym PEMPHIGUS is suggested to encompass the numerous factors involved in the pathogenesis and course of the disease. In the following review the authors present studies documenting these ...